- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CADRENAL THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 31.03. | Cadrenal Therapeutics GAAP EPS of -$6.64 | 1 | Seeking Alpha | ||
| 31.03. | Cadrenal meldet Quartalsverlust und schließt FDA-Gespräche zu HIT-Therapie ab | 1 | Investing.com Deutsch | ||
| 31.03. | Cadrenal reports Q4 loss, completes FDA meeting on HIT therapy | 1 | Investing.com | ||
| 31.03. | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting | 129 | GlobeNewswire (Europe) | PONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic... ► Artikel lesen | |
| 31.03. | Cadrenal Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 31.03. | Cadrenal Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.03. | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes | 6 | GlobeNewswire (USA) | ||
| 12.03. | Cadrenal Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.03. | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion | 156 | GlobeNewswire (Europe) | Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla.... ► Artikel lesen | |
| 24.02. | Cadrenal: Positive Signale bei Thrombose-Studie trotz verfehltem Primärziel | - | Investing.com Deutsch | ||
| 24.02. | Cadrenal's CAD-1005 shows reduction in blood clots in HIT trial | 1 | Investing.com | ||
| 24.02. | Cadrenal Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.02. | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement | 511 | GlobeNewswire (Europe) | Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase... ► Artikel lesen | |
| 12.01. | Cadrenal: 12-LOX-Inhibitor zeigt Potenzial bei seltener Blutgerinnungsstörung | - | Investing.com Deutsch | ||
| 12.01. | Cadrenal highlights potential of 12-LOX inhibitor for blood disorder | 1 | Investing.com | ||
| 30.12.25 | Cadrenal Therapeutics: Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System | 420 | ACCESS Newswire | PONTE VEDRA, FL / ACCESS Newswire / December 30, 2025 / Some companies enter a market because they see opportunity. Others step in because the situation has become unsustainable, and someone has to... ► Artikel lesen | |
| 29.12.25 | Cadrenal Therapeutics: Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On | 322 | ACCESS Newswire | PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its forgotten corners. In anticoagulation, those corners turned into entire neighborhoods. For years, the field centered itself... ► Artikel lesen | |
| 24.12.25 | Cadrenal Therapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 23.12.25 | Cadrenal Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.12.25 | Cadrenal Therapeutics: Cadrenal's Quiet Expansion Play Is Starting to Get Loud | 633 | ACCESS Newswire | PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) entered the back half of the year with a calm, almost surgical approach to building out its foundation. While... ► Artikel lesen |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,15 | +0,22 % | Durchbruch in der Psychotherapie: Emyria meldet 50% Remission - Ein neuer "BioNTech-Moment" für die Mental-Health-Branche? | ||
| EVOTEC | 5,350 | -0,93 % | RBC stuft Evotec auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Evotec auf "Outperform" mit einem Kursziel von 10 Euro belassen. Charles Weston passte seine Prognosen und das Bewertungsmodell... ► Artikel lesen | |
| BB BIOTECH | 48,550 | +0,21 % | BB Biotech AG: Portfolio-Umbau zahlt sich aus - Aktie schlägt Index trotz schwierigem Umfeld | Die Beteiligungsgesellschaft BB Biotech meldet sich eindrucksvoll zurück: Im 1. Quartal 2026 gelingt nicht nur eine stabile Performance - der Aktienkurs schlägt sogar den Nasdaq Biotechnology Index.... ► Artikel lesen | |
| AMGEN | 295,40 | +0,44 % | Amgen Announces Retirement Of David M. Reese, Executive Vice President And Chief Technology Officer | Organizational Changes Further Emphasize Integration of Biology and Technology
THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced... ► Artikel lesen | |
| NOVAVAX | 6,960 | -0,85 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| BIOGEN | 156,62 | -0,43 % | Biogen To Acquire TJ Bio's Rights To Felzartamab In The Greater China Region | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and TJ Biopharma have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,050 | +0,18 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,508 | -0,45 % | Quantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions in Quantum and Cyber Defense Sectors | BERKELEY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber (the "Company" or "Quantum Cyber"), today announced a strategic update in response... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,660 | +0,17 % | Intellia to report Phase 3 CRISPR gene editing trial results Monday | ||
| TEMPUS AI | 44,665 | +0,42 % | Tempus AI Nears Profitability as Operating Leverage Emerges | ||
| BIOCRYST PHARMACEUTICALS | 7,620 | -0,18 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,380 | -1,55 % | NurExone Biologic: 100% Erfolgsquote bei Querschnittlähmung! | ||
| BIOMARIN PHARMACEUTICAL | 45,390 | +0,04 % | BioMarin Appoints Ian Clark As Board Chair | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN), on Tuesday, announced the appointment of Ian Clark as Chair of the Board, subject to his election at the company's Annual Meeting... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,280 | -0,23 % | Mesoblast: Neue Fantasie durch Technologie - und ein wachsender Zielmarkt | ||
| EXELIXIS | 37,955 | -1,04 % | RBC Capital reiterates Exelixis stock rating on competitive position |
CADRENAL THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 5,440 Euro und damit +0,74 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CADRENAL THERAPEUTICS INC finden Sie auf Wallstreet Online.